Résultats de la recherche - 5 results
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
(2023) Keywords: Alpha COVID-19 Delta Vaccine effectiveness Health Topics: Acute respiratory tract infection Acute luchtweginfectie Infection respiratoire aiguë Service: Maladies virales Virale ziekten ...
Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions.
Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group Source: Lancet Microbe (2023) Health Topics: Acute respiratory tract infection Acute ...
Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022.
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in early 2020 and subsequent implementation of public health and social measures (PHSM) disrupted the epidemiology of respiratory viruses. This work describes the ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose. Health Topics: Acute ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
a first booster dose during the latter period increased VE to over 90%. Health Topics: Acute luchtweginfectie Acute respiratory tract infection Infection respiratoire aiguë Service: Épidémiologie des ...